Your browser doesn't support javascript.
loading
Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial.
Tolaney, Sara M; Wardley, Andrew M; Zambelli, Stefania; Hilton, John F; Troso-Sandoval, Tiffany A; Ricci, Francesco; Im, Seock-Ah; Kim, Sung-Bae; Johnston, Stephen Rd; Chan, Arlene; Goel, Shom; Catron, Kristen; Chapman, Sonya C; Price, Gregory L; Yang, Zhengyu; Gainford, M Corona; André, Fabrice.
Afiliación
  • Tolaney SM; Dana-Farber Cancer Institute, Boston, MA, USA. Electronic address: sara_tolaney@dfci.harvard.edu.
  • Wardley AM; The NIHR Manchester Clinical Research Facility at The Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK; Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology Medicine and Health, University of Manchester, Manchester, UK.
  • Zambelli S; Istituto Di Ricovero e Cura a Carattere Scientifico, Ospedale San Raffaele, IRCCS, Milano, Italy.
  • Hilton JF; Department of Medicine, Division of Medical Oncology, The Ottawa Hospital and University of Ottawa, Ottawa, Canada.
  • Troso-Sandoval TA; Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Ricci F; Institut Curie, PSL Research University, Department of Medical Oncology, Paris, France.
  • Im SA; Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea.
  • Kim SB; Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
  • Johnston SR; Royal Marsden Hospital, London, UK.
  • Chan A; Breast Cancer Research Centre-WA, Nedlands, WA, Australia; Curtin University, Nedlands, WA, Australia.
  • Goel S; Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; The Sir Peter MacCallum Department of Medical Oncology, University of Melbourne, Melbourne, VIC, Australia.
  • Catron K; Eli Lilly, Indianapolis, IN, USA.
  • Chapman SC; Eli Lilly, Windlesham, UK.
  • Price GL; Eli Lilly, Indianapolis, IN, USA.
  • Yang Z; Eli Lilly, Indianapolis, IN, USA.
  • Gainford MC; Eli Lilly, Indianapolis, IN, USA.
  • André F; Gustave Roussy, Université Paris Saclay, INSERM, Villejuif, France.
Lancet Oncol ; 21(6): 763-775, 2020 06.
Article en En | MEDLINE | ID: mdl-32353342
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Bencimidazoles / Neoplasias de la Mama / Protocolos de Quimioterapia Combinada Antineoplásica / Receptores de Estrógenos / Receptor ErbB-2 / Antagonistas del Receptor de Estrógeno / Trastuzumab / Antineoplásicos Inmunológicos / Fulvestrant / Aminopiridinas Tipo de estudio: Clinical_trials Límite: Aged / Female / Humans / Middle aged País/Región como asunto: America do norte / America do sul / Argentina / Asia / Brasil / Europa / Oceania Idioma: En Revista: Lancet Oncol Asunto de la revista: NEOPLASIAS Año: 2020 Tipo del documento: Article Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Bencimidazoles / Neoplasias de la Mama / Protocolos de Quimioterapia Combinada Antineoplásica / Receptores de Estrógenos / Receptor ErbB-2 / Antagonistas del Receptor de Estrógeno / Trastuzumab / Antineoplásicos Inmunológicos / Fulvestrant / Aminopiridinas Tipo de estudio: Clinical_trials Límite: Aged / Female / Humans / Middle aged País/Región como asunto: America do norte / America do sul / Argentina / Asia / Brasil / Europa / Oceania Idioma: En Revista: Lancet Oncol Asunto de la revista: NEOPLASIAS Año: 2020 Tipo del documento: Article Pais de publicación: Reino Unido